The approval of ACQUITY UPLC is important for Waters as well as China. Notably, this marks the second medical device approval for Waters, the first being a neonatal screening solution which included ...

MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE:WAT) announced today the introduction of the ACQUITY™ UPLC PLUS Series, three new ACQUITY UltraPerformance LC™ (UPLC™) Systems that build off ...

Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Request A Quote Download PDF Copy Request A Quote Download ...

ACQUITY™ Premier UPLC™ System: The next evolution in separation science is here. Maximizing the sensitivity, repeatability, and robustness of your LC and LC-MS applications is critical. The ACQUITY ...

The company’s next-generation ultraperformance liquid chromatography platform is designed to meet the evolving laboratory requirements for chromatographic performance. Waters’ Acquity ultraperformance ...

Waters Corporation celebrated the ten-year anniversary of the ACQUITY UltraPerformance LC (UPLC) System. Over the last ten years, ACQUITY UPLC has had a major effect on laboratories worldwide, both ...

The ACQUITY UPLC I-Class PLUS System offers industry-leading separations performance, opening up new possibilities for maximizing the resolution and sensitivity of your methods, improving the ...

“In 2004, we changed the game. High Performance Liquid Chromatography (HPLC) wasn't keeping pace with business demands to analyze more samples, faster and with better results. The introduction of ...

Waters Corporation announced that the Waters ACQUITY UPLC I-Class IVD/Xevo TQ-S micro IVD System is now manufactured as a U. FDA Class I medical device and is CE Marked to the European Directive 98/79 ...

Waters Corporation's ( WAT) ACQUITY UPLC TQD system has been approved as a medical device by the Chinese Food and Drug Administration and can now be legally promoted and sold in China. This device ...